GlassScriptPhysician profile
Nanette Silverberg
NPI 1316933740
$336,574.71
in general payments reported to CMS, 2019-2025
31 companies · $106K in 2025
The $106K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $24K · 2021: $8,721 · 2022: $58K · 2023: $42K · 2024: $68K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Consulting Fee: $51K · Honoraria: $27K · Travel and Lodging: $11K · Education: $9,963 · Food and Beverage: $7,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,096.00 |
| Consulting Fee | $51,405.06 |
| Honoraria | $26,850.00 |
| Travel and Lodging | $10,589.70 |
| Education | $9,962.61 |
| Food and Beverage | $7,808.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $94,589.63 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $90,025.99 | 2019-2025 | Dupixent |
| Pfizer INC. | $40,997.55 | 2019-2025 | |
| Lnhc, INC | $17,881.10 | 2024-2025 | Zelsuvmi |
| Eli Lilly and Company | $15,262.38 | 2022-2025 | Ebglyss, Taltz |
| Abbvie INC. | $14,762.93 | 2019-2025 | Rinvoq, Skyrizi |
| Alk-Abello, INC | $13,227.67 | 2024 | Grastek, Odactra, Ragwitek |
| Genzyme Corporation | $12,498.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12,189.06 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $11,027.71 | 2023-2025 | Ycanth |
| Dermavant Sciences, INC. | $3,399.41 | 2023-2024 | Vtama |
| Leo Pharma INC. | $2,797.88 | 2022-2025 | Adbry, Anzupgo |
| Vyne Pharmaceuticals INC. | $2,163.60 | 2021 | |
| Avita Medical Americas, LLC | $1,642.21 | 2023-2025 | Recell, Cohealyx, Permeaderm |
| Amryt Pharma Holdings LTD | $1,598.83 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $556.52 | 2019-2021 | |
| Lilly USA, LLC | $387.83 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Organon LLC | $298.38 | 2025 | Vtama |
| Dr.Reddy'S Laboratories,INC. | $260.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $182.43 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $164.48 | 2020-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.62 | 2019 | |
| Janssen Biotech, INC. | $141.33 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $79.49 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $73.98 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $73.76 | 2024 | Zoryve |
| Amgen INC. | $46.56 | 2024 | Actimmune |
| Sun Pharmaceutical Industries INC. | $45.73 | 2022 | |
| Dermira, INC. | $22.73 | 2021 | |
| Journey Medical Corporation | $20.54 | 2023 | |
| Horizon Therapeutics Plc | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanette Silverberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.